c19early.org COVID-19 treatment researchVitamin B9Vitamin B9 (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
 
More

Supplementary Data — Vitamin B9 for COVID-19: real-time meta analysis of 16 studies (11 treatment studies and 5 sufficiency studies)

@CovidAnalysis, December 2024, Version 7V7
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bejan 9% 0.91 [0.33-2.53] death 353 (n) 8,853 (n) Improvement, RR [CI] Treatment Control Bejan 1% 0.99 [0.38-2.53] ventilation 355 (n) 8,874 (n) Bejan 17% 0.83 [0.34-2.02] ICU 356 (n) 8,911 (n) Meisel 27% 0.73 [0.26-2.04] death 23 (n) 310 (n) Meisel 6% 0.94 [0.43-2.07] death/int. 23 (n) 310 (n) Bliek-Bueno -87% 1.87 [1.51-2.33] death 8,570 (all patients) CT​1 Bliek-Bueno -170% 2.70 [1.83-3.99] death 8,570 (all patients) CT​1 Bliek-Bueno -59% 1.59 [1.21-2.04] death 8,570 (all patients) CT​1 Deschasaux-Tanguy 16% 0.84 [0.72-0.98] cases 7,766 (all patients) per SD change Monserrat .. (PSM) -132% 2.32 [1.36-4.08] death n/a n/a Nimer 28% 0.72 [0.42-1.23] hosp. 16/213 203/1,935 Nimer 28% 0.72 [0.43-1.15] severe case 19/213 241/1,935 MacFadden 0% 1.00 [0.93-1.07] cases n/a n/a Loucera 1% 0.99 [0.81-1.20] death 624 (n) 15,344 (n) Topless -164% 2.64 [2.15-3.24] death population-based cohort Topless -51% 1.51 [1.42-1.61] cases population-based cohort Farag (CLUS. RCT) 88% 0.12 [0.04-0.36] cases 4/224 20/139 Farag (CLUS. RCT) 66% 0.34 [0.16-0.75] cases 8/163 20/139 Akbar -18% 1.18 [0.83-1.66] cases 316 (n) 9,684 (n) Vitamin B9 COVID-19 outcomes c19early.org December 2024 1 CT: study uses combined treatment Favors vitamin B9 Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit